重症监护室体外肝脏治疗的不良事件与短期和长期结局:单中心16年MARS®应用经验
该研究连续前瞻性纳入2005年3月至2021年8月单中心ICU接受MARS®治疗的全部住院病例,共180例次,主要终点为MARS®相关不良事件发生率,次要终点为生物学与临床效果。结果:95例次(52.8%)发生至少1次不良事件,血小板减少最常见(55例次,30.6%);血小板计数治疗前131(±95)×10^9/L,治疗后106(±72)×10^9/L(p<.001)。治疗后总胆红素在所有组均显著下降(p<0.05),慢加急性肝衰竭与急性肝衰竭组肝性脑病显著改善(p=0.01),瘙痒组瘙痒强度评分显著下降(p<0.01)。作者结论:MARS®治疗不良事件常见,但各应用均有显著临床与生物学改善。
要点
- 180例次MARS®治疗中95例次(52.8%)发生至少1次不良事件,血小板减少最常见(55例次,30.6%)。
- 血小板计数MARS®治疗前131(±95)×10^9/L vs 治疗后106(±72)×10^9/L(p<.001)。
- MARS®治疗后总胆红素在所有组均显著下降(p<0.05)。
- 慢加急性肝衰竭与急性肝衰竭组肝性脑病在MARS®治疗后显著改善(p=0.01)。
- 瘙痒组瘙痒强度评分在MARS®治疗后显著下降(p<0.01)。
适用人群与场景
- 2005年3月至2021年8月单中心ICU连续前瞻性纳入的接受MARS®治疗的住院病例,共180例次。
- 适应症构成:慢加急性肝衰竭56例次(31.1%)、急性肝衰竭32例次(17.8%)、术后肝衰竭28例次(15.5%)、瘙痒52例次(28.9%)、药物中毒12例次(6.7%)。
研究设计与关键结果
- 研究类型:单中心连续前瞻性队列,共180例次ICU住院接受MARS®治疗。
- 主要终点:至少1次不良事件发生于95例次(52.8%);血小板减少最常见,55例次(30.6%)。
- 血小板计数:MARS®治疗前131(±95)×10^9/L vs 治疗后106(±72)×10^9/L(p<.001)。
- 总胆红素:MARS®治疗后所有组均显著下降(p<0.05)。
- 肝性脑病:慢加急性肝衰竭组与急性肝衰竭组均显著改善(p=0.01)。
- 瘙痒:瘙痒组瘙痒强度评分在MARS®治疗后显著下降(p<0.01)。
证据类型、等级与局限
- 证据类型:单中心连续前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 接受MARS®治疗的ICU患者中不良事件常见(52.8%),血小板减少发生率为30.6%,治疗前后血小板计数分别为131(±95)×10^9/L与106(±72)×10^9/L(p<.001)。
- MARS®治疗后总胆红素在所有组显著下降(p<0.05),慢加急性肝衰竭与急性肝衰竭组肝性脑病显著改善(p=0.01),瘙痒组瘙痒强度评分显著下降(p<0.01)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Molecular Adsorbent Recirculating System (MARS®) is a non-biological artificial liver device. The benefit risk ratio between uncertain clinical effects and potential adverse events remains difficult to assess. We sought to describe adverse events related to MARS® therapy as well as biological and clinical effects.
METHODS: All intensive care unit (ICU) admissions to whom MARS® therapy was prescribed from March 2005 to August 2021 were consecutively and prospectively included. The main endpoint was the incidence of adverse events related to MARS® therapy. Secondary endpoints were the biological and clinical effects of MARS® therapy.
RESULTS: We reported 180 admissions treated with MARS® therapy. Among the 180 admissions, 56 (31.1%) were for acute-on-chronic liver failure, 32 (17.8%) for acute liver failure, 28 (15.5%) for post-surgery liver failure, 52 (28.9%) for pruritus and 12 (6.7%) for drug intoxication. At least one adverse event occurred in 95 (52.8%) admissions. Thrombocytopenia was the most frequent adverse event which was recorded in 55 admissions (30.6%). Overall, platelets count was 131 (± 95) × 109/L before and 106 (± 72) × 109/L after MARS® therapy (p < .001). After MARS® therapy, total bilirubin was significantly decreased in all groups (p < 0.05). Hepatic encephalopathy significantly improved in both the acute-on-chronic and in the acute liver failure group (p = 0.01). In the pruritus group, pruritus intensity score was significantly decreased after MARS® therapy (p < 0.01).
CONCLUSION: In this large cohort of patients treated with MARS® therapy we report frequent adverse events. Thrombocytopenia was the most frequent adverse event. In all applications significant clinical and biological improvements were shown with MARS® therapy.
参考来源
- Monet C, De Jong A, Aarab Y, et al. Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center. Crit Care. 2022. PMID: 36123713. doi:10.1186/s13054-022-04165-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。